Publication | Closed Access

1162 RIBAVIRIN DOSE MODIFICATION IN TREATMENT-NAIVE AND PREVIOUSLY TREATED PATIENTS WHO RECEIVED TELAPREVIR COMBINATION TREATMENT: NO IMPACT ON SUSTAINED VIROLOGIC RESPONSE IN PHASE 3 STUDIES

PharmacologyAntiviral Drug DevelopmentHepatitisVirologyAntiviral TherapyPharmacotherapyAntiviral DrugMedicine